Clinical trial Recruiting at 1 site Interventional Ages 18 to 60

Evaluating the impact of adrenal artery embolization on heart changes in patients with primary aldosteronism

Official title: The Effect of Selective Adrenal Artery Embolization and Spironolactone on Ventricular Remodeling in Nondominant Lateral Secretory Primary Aldosteronism: A Randomized Controlled Clinical Study

Run by Second Affiliated Hospital of Nanchang University · NCT05501080 · Data updated 2026-11-12

This study is testing whether a procedure called adrenal artery embolization can improve heart changes in people with primary aldosteronism compared to taking a medication called spironolactone.

More Primary Aldosteronism trials

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment112 (estimated)
SponsorSecond Affiliated Hospital of Nanchang University
Academic / other
Locations1 site (Nanchang)
StatusRecruiting
StartedSeptember 1, 2022
Main results expectedSeptember 1, 2025
Study endsDecember 31, 2025
Registry record updatedMay 16, 2025
Trial IDNCT05501080 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-60 with confirmed bilateral primary aldosteronism and specific blood pressure criteria.

Probably not a fit

Patients with primary hypertension or secondary hypertension from other causes will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of superselective adrenal artery embolization on ventricular remodeling in patients diagnosed with primary aldosteronism, specifically those without lateralized aldosterone secretion. Participants will undergo a 2-week screening to determine eligibility and will then be randomized into two groups: one receiving the embolization procedure and the other receiving spironolactone therapy. The aim is to compare the outcomes of these two treatment approaches in managing the condition.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option that may improve heart health in patients with primary aldosteronism.

How similar studies have gone: While similar approaches have been explored, this specific intervention in the context of primary aldosteronism is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* (1) Age 18-60 years old, regardless of gender;
* (2) Blood pressure conditions meet one of the following: 1) Office blood pressure ≥ 140/90mmHg; 2) Ambulatory blood pressure monitoring whole day blood pressure \> 130/80 mmHg or daytime blood pressure \> 135/85 mmHg;
* (3) After strict drug elution, it met the diagnostic criteria of primary aldosteronism, and bilateral primary aldosteronism was confirmed by adrenal venous sampling;
* (4) No surgical intent or contraindication to surgery and willing to undergo pharmacological treatment or percutaneous superselective adrenal artery embolization;
* (5) The patient or his/her legal representative shall sign the written informed consent approved by the ethics committee before the screening.

Exclusion Criteria:

* (1) Primary hypertension or secondary hypertension with other causes;
* (2) A woman who is pregnant or lactating, or has a birth plan for the next year;
* (3) There are serious organic diseases, especially liver and kidney dysfunction(eGFR\<45 mL/min/1.73 m2);
* (4) Severe allergy to contrast medium;
* (5) Other serious organic diseases, life expectancy \< 12 months;
* (6) Adrenal CT showed adenoma.;
* (7) Patients are enrolled or want to participate in other clinical studies. During the enrollment study, the results of this study will be affected.

Where it's running

  • The Second Affiliated Hospital of Nanchang University
    Nanchang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.